OncoSec Medical Incorporated (ONCS) EPS Estimated At $-0.23

December 20, 2017 - By Peter Erickson

 OncoSec Medical Incorporated (ONCS) EPS Estimated At $ 0.23

Analysts expect OncoSec Medical Incorporated (NASDAQ:ONCS) to report $-0.23 EPS on December, 21.They anticipate $0.06 EPS change or 20.69 % from last quarter’s $-0.29 EPS. After having $-0.28 EPS previously, OncoSec Medical Incorporated’s analysts see -17.86 % EPS growth. The stock increased 1.80% or $0.03 during the last trading session, reaching $1.7. About 430,391 shares traded. OncoSec Medical Incorporated (NASDAQ:ONCS) has declined 34.57% since December 20, 2016 and is downtrending. It has underperformed by 51.27% the S&P500.

OncoSec Medical Incorporated (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 9 analyst reports since March 9, 2016 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, November 9. The firm has “Buy” rating by H.C. Wainwright given on Friday, June 2. The firm has “Buy” rating given on Thursday, July 21 by Rodman & Renshaw. The firm earned “Buy” rating on Tuesday, June 13 by Noble Financial. The stock of OncoSec Medical Incorporated (NASDAQ:ONCS) earned “Buy” rating by H.C. Wainwright on Wednesday, March 9. The firm has “Buy” rating by Maxim Group given on Friday, June 2. H.C. Wainwright maintained it with “Buy” rating and $600 target in Monday, June 12 report. The rating was maintained by Maxim Group with “Buy” on Thursday, June 8. As per Friday, December 15, the company rating was maintained by H.C. Wainwright.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. The company has market cap of $60.38 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. It currently has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

More news for OncoSec Medical Incorporated (NASDAQ:ONCS) were recently published by: Prnewswire.com, which released: “OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief …” on December 05, 2017. Prnewswire.com‘s article titled: “OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b …” and published on December 14, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.